^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study. (PubMed, Lancet Haematol)
    These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies.
    P2 data • Preclinical • Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    1d
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1, N=16, Completed, Providence Health & Services | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cyclophosphamide • citoplurikin (IRX-2)
    1d
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    2d
    GVHD-PTCy: Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Milton S. Hershey Medical Center | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    cyclophosphamide
    2d
    Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. (PubMed, Front Immunol)
    This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide • tofacitinib
    2d
    Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=216, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (clinicaltrials.gov)
    P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone
    2d
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    2d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    3d
    CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML (clinicaltrials.gov)
    P1/2, N=32, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • CD19-CAR_Lenti T cells
    3d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    3d
    Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P2/3, N=437, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting | Initiation date: Jul 2026 --> Nov 2025
    Enrollment closed • Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • Stivarga (regorafenib) • ifosfamide • etoposide IV • irinotecan • vincristine